Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 11NIH 8NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 12CNS 10Gastrointestinal 7Head & Neck 6Thoracic 3Tumor-Agnostic 1Sarcoma 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Radiotherapy 34Gemcitabine 24Docetaxel 24bicalutamide 23Goserelin 21Paclitaxel 19Cisplatin 19Doxorubicin 18Carboplatin 18Flutamide 17Leuprolide 16Radiotherapy, Conformal 13Etoposide 13Filgrastim 12Prednisone 11Gene Expression Profiling 11Gonadotropin-Releasing Hormone 10Radiotherapy, Intensity-Modulated 9Vincristine 8Vinblastine 8Triptorelin Pamoate 8Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Buserelin 8Androgen Antagonists 8Surgical Procedures, Operative 7Radiation 7Polymerase Chain Reaction 7Methotrexate 7Estramustine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Platinum × Genitourinary × Clear all
NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

SWOG Cancer Research Network

Phase 2 Terminated
6 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡